Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

A phase II multicenter study of NASOX regimen as adjuvant chemotherapy for patients with resected pancreatic ductal adenocarcinoma.

View Full Paper
Ask AI
Bookmark
Share

Authors

KJKuirong JiangMTMin TuQWQianqian Wang

Discussion

Loading...

Member takes

Overview

Phase II trial evaluates NASOX's efficacy in improving outcomes for resected pancreatic cancer, highlighting its potential benefits.

Key Points

  • This study aims to evaluate the efficacy and safety of the NASOX regimen as an adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma.
  • Phase II, single-arm, open-label multicenter clinical trial
  • 53 patients with resected PDAC enrolled
  • Primary endpoint focused on disease-free survival (DFS), with safety and overall survival as secondary endpoints.
  • 9-month DFS rate of 82.7% and 9-month OS rate of 97.7% observed
  • Treatment-related adverse events occurred in 100% of patients, with 53.85% experiencing grade 3 or 4 events
  • Common grade 3–4 adverse events included diarrhea (17.31%) and neutropenia (17.31%).

Cite This Study

Jiang et al. (2026) studied this question.

synapsesocial.com/papers/6a192d13fab5b468c4415da3https://doi.org/10.1200/jco.2026.44.16_suppl.4230
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neoadjuvant NASOX for pancreatic cancer: A prospective multicenter study.2026
  2. 2Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.2026
  3. 3First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study2025 · 5 citations
  4. 4Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial2024 · 11 citations
  5. 5NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data2025 · 5 citations